Showing 5461-5470 of 5621 results for "".
- Oculis Elects Anthony Rosenberg and David A. Weber to Its Board of Directorshttps://modernod.com/news/oculis-elects-anthony-rosenberg-and-david-a-weber-to-its-board-of-directors/2479867/Oculis announced the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, PhD, as Non-Executive Director. Together, they bring more than 60 years’ experience from the global pharmaceutical and eye care industries to the compa
- IOT Launches New Corporate Brandinghttps://modernod.com/news/iot-launches-new-corporate-branding/2479870/Optical technology company IOT has announced a change in brand identity as part of an overall strategy to better communicate its culture, values, and approach to market. The new website and social media profiles are designed to help the company share optical knowledge as well as information abou
- Allergan Announces New Partnership With the International Diabetes Federationhttps://modernod.com/news/allergan-announces-new-partnership-with-the-international-diabetes-federation/2479873/Allergan has announced a collaborative partnership with the International Diabetes Federation (IDF) with the aim of developing a global approach to screen, diagnose, and manage diabetic macular edema (DME). Diabetic eye health is a key concern for IDF and Allergan. The partnership will bri
- Neurolens Appoints Thomas J. Chirillo as Chief Commercial Officerhttps://modernod.com/news/neurolens-appoints-thomas-j-chirillo-as-chief-commercial-officer/2479876/Neurolens announced the appointment of Thomas J. Chirillo as Chief Commercial Officer. An accomplished senior healthcare executive with deep experience in the eye care space, Mr. Chirillo brings almost 4 decades of sales and marketing experience to neurolens. “We’re thrilled to have someon
- FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Diseasehttps://modernod.com/news/fda-grants-lin-bioscience-rare-pediatric-disease-status-for-lbs-008-to-treat-stargardt-disease/2479877/Lin BioScience announced that the FDA has granted rare pediatric disease (RPD) designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. The Priority Review Voucher Program is intended to encourage development of therapies to prevent and treat rare pedi
- Heidelberg Engineering OCT Angiography Module Now Available in the United Stateshttps://modernod.com/news/heidelberg-engineering-oct-angiography-module-now-available-in-the-united-states/2479879/Heidelberg Engineering announced that it has received FDA clearance for its OCT Angiography Module (OCTA). The additional module is now available for new and existing Spectralis upgradeable diagnostic imaging devices.
- Chinese Regulators Clear Takeda’s $62-Billion Takeover of Shirehttps://modernod.com/news/chinese-regulators-clear-takedas-62-billion-takeover-of-shire/2479882/Takeda said that China’s State Administration for Market Regulation has granted unconditional approval of its proposed $62-billion purchase of Shire. The Japanese drugmaker expects to complete the transaction in the first half of next year. China’s regulatory clearance “
- Market Scope: Ophthalmic Laser Market Expected to Total $400 Million in 2018https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-400-million-in-2018/2479885/Global revenues for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total more than $400 million in 2018 and grow
- Ziemer to Implement Low Energy Lenticule Extraction Applications for its Femtosecond Laser Platformhttps://modernod.com/news/ziemer-announces-to-implement-low-energy-lenticule-extraction-applications-to-its-femtosecond-laser-platform/2479888/Ziemer Ophthalmic Systems announced plans to incorporate lenticule extraction capabilities for its flagship LDV Z8 femtosecond laser system.1 “From the very first days of developing the femtosecond l
- FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy/2479893/Regeneron Pharmaceuticals announced that the FDA has accepted for review the supplemental biologics license application of Eylea (aflibercept) injection for the treatment of diabetic retinopathy (DR). The target action date for the FDA decision is May 13, 2019. The supplemental biologics l